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Abstract 
CD91 is a scavenger receptor expressed by different immune cells and its ligands defensins 
have been demonstrated to contribute to immune responses against infections and tumors. 
We previously demonstrated that CD91 is expressed on human monocyte-derived dendritic 
cells (moDCs) and that human defensins stimulate in vitro the activation of these cells. In 
this study, we observed that CD91 is expressed at different levels on two distinct moDC 
subsets: CD91dim and CD91bright moDCs. Although CD91bright moDCs represented a small 
proportion of total moDCs, this subset showed higher levels of activation and maturation 
markers compared to CD91dim moDCs. The frequency of CD91bright moDCs increased by 
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~50% after in vitro stimulation with recombinant Human Neutrophil Peptide-1 (rHNP-1) and 
recombinant Human Beta Defensin-1 (rHBD-1), while lipopolysaccharide (LPS) stimulation 
decreased it by ~35%. Both defensins up-regulated moDC expression of CD80, CD40, 
CD83 and HLA-DR, although to a lower extent compared with LPS. Notably, upon culture 
with rHNP-1 and rHBD-1, CD91bright moDCs maintained their higher activation/maturation 
status, while this was lost upon culture with LPS. Our findings suggest that defensins 
promote the differentiation into activated CD91bright DCs and may encourage the exploitation 
of the CD91/defensins axis as a novel therapeutic strategy to potentiate antimicrobial and 
antitumor immune response. 
 
Introduction 
CD91 is a member of the Low-density lipoprotein receptor family that recognizes more than 
40 structurally and functionally distinct ligands.1 Particularly, CD91 has been demonstrated 
to bind and internalize α2-Macroglobulin,2 C1q3 and defensins.4 Reflecting this diversity of 
ligands, CD91 displays a wide tissue distribution and participates in a variety of physiological 
responses, including lipoprotein metabolism, proteinase homeostasis and cell migration. 
Subsequent studies defined CD91 as an immunologically relevant receptor for Heat Shock 
Proteins (HSPs) and molecular chaperones.5,6 It is expressed on different cell types, 
including dendritic cells, monocytes, macrophages, B and T cells as well as splenocytes and 
thymocytes.7 In addition, CD91 is expressed on monocyte-derived dendritic cells (moDCs) 
and it plays a role in the internalization of CD91-targeted antigens and their presentation to T 
cells.8 Moreover, the importance of this molecule in the immune response has been 
strengthened by the observation that CD91 represents an important route for stimulating 
CD8+ T cell responses by MHC class I-restricted presentation.9 
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The scavenger receptor CD91 is involved in wide a variety of diseases and infections.  
Kebba et al, showed that a significantly higher surface expression of CD91 on monocytes of 
human immunodeficiency virus type-1 (HIV-1)-infected long-term nonprogressors may 
contribute to host anti-HIV-1 defence and play a role in protection against HIV-1 infection.10 
Further, the up-regulation of CD91 in patients affected by cancer may represent an 
additional strategy to improve DC activation and subsequent stimulation of a specific CD8+ 
T cell response towards tumor cells dying an immunogenic cell death.11 Of note, CD91 
ligands HSPs, α2-Macroglobulin and defensins are currently under investigation in pre-
clinical and clinical trials exploring new therapeutic strategies for the treatment of infectious 
diseases and cancers.12,13,14  
 
In a previous study, we demonstrated that moDCs express CD91 and that moDC treatment 
with human defensins up-regulates the surface expression of CD91 as well as the 
activation/maturation markers on these cells.15 In this study, we described two subsets of 
moDCs, characterized by variable level of CD91 expression and different state of 
activation/maturation. We further investigated the effects of recombinant human alpha and 
beta defensins, Human Neutrophil Peptide-1 (HNP-1) and Human Beta Defensin-1 (rHBD-
1), on these two subsets of moDCs. 
 
Materials and Methods 
In vitro culture of moDCs 
Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient 
centrifugation from standard buffy coat preparations of healthy donors. Monocytes were 
obtained from adherent PBMCs (> 90% pure CD14+, as assessed by flow cytometry) and 
cultured in RPMI-1640 (Euroclone, Wetherby, UK) supplemented with 10% heat-inactivated 
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fetal calf serum (Gibco, Invitrogen Co., Carlsbad, CA, USA), in the presence of 800 U/ml 
recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF; 
Strathmann Biotech, Hannover, Germany) and 10 ng/ml rhIL-4 (R&D Systems) at 37°C in 
5% CO2 for 5 days. Immature moDCs were characterized by long dendrites and expression 
of high levels of CD1a (>90%) and low levels of CD14 (<5%). Cell viability was > 90% in all 
experiments, as assessed by trypan blue exclusion. These immature moDCs were 
stimulated for 18 hr by adding full-length 100 ng/ml rHNP-1 (30 aa), 500 ng/ml rHBD-1 (36 
aa; both from AlphaDiagnostic, San Antonio, TX, USA), 20 μg/ml HSP90 (Enzo Life 
Sciences, Lausen, Switzerland), or 100ng/ml lipolysaccharide (LPS) (serotype 055:B5, 
Sigma Chemicals Co., St. Louis, MO, USA). The concentration and the duration of culture 
stimulation were established based on preliminary experiments.15 Endotoxin contamination 
in culture media and defensins was excluded by Limulus amoebocyte lysate assay 
(BioWhittaker, Walkersville, MD, USA) following the manufacturer’s protocol. 
 
Flow cytometric analysis 
Phenotypic analysis was performed by 5-color flow cytometry. Briefly, 1x105 cells were 
incubated for 20 min at 4°C with different mAbs: anti-CD91 FITC- (Biomac, Leipzig, 
Germany), -CD80 PE-, -CD86 APC-, -CD1a PE-, -CD83 APC-, -CD14 APC-, -CD40 PE-, -
CCR7 PE-, HLA-DR APC-Cy7-conjugated (all from BD Biosciences, San Diego, Ca, USA). 
To optimize the staining, mAbs were titrated in preliminary experiments. 7-Amino-
actinomycin D (7-AAD, Sigma Aldrich) was used to exclude non-viable cells from the 
analysis. Fluorescence minus one (FMO) samples were used as negative controls. 
 
Cells were collected and analyzed using a FACSCanto II (Becton Dickinson) flow cytometer, 
and data analysis was performed using FACSDiva (Becton Dickinson) and FlowJo software 
(TreeStar Inc., Ashland, OR, USA). 
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Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5.0a (GraphPad Software, San 
Diego, CA). All statistical analyses assumed a two-sided significance level of p< 0.05. The 
Student’s paired t-test was used for comparisons between groups. 
 
Results 
Different levels of CD91 identify two moDC subpopulations 
Others and we previously showed that CD91 is expressed on moDCs.9,15-17 However, 
whether CD91 is expressed differently in moDC subpopulations is still unknown. To 
investigate the expression of CD91 receptor, we cultured human monocytes with GM-CSF 
and IL-4 for 5 days to generate immature moDCs that were subsequently characterized by 
flow cytometry. As expected,15 we observed that during the differentiation of monocytes into 
moDCs characterized by down-regulation of CD14 and up-regulation of CD1a (Figure 1A), a 
partial down-regulation of CD91 occurred in parallel (Figure 1B). Moreover, our results 
clearly showed that CD91+ moDCs are segregated into two distinct populations: CD91 is 
highly expressed in a small proportion of total moDCs (CD91bright moDCs) (mean ± SE, 
1.19% ± 0.28), while the majority of cells expressed low levels of CD91 receptor (CD91dim 
moDCs) (Figure 2A). 
 
CD91bright moDCs show an activated phenotype 
The ability of DCs to activate immune responses depends on their maturation status and the 
expression of costimulatory molecules. In order to investigate whether CD91bright and 
CD91dim subsets differ in term of activation/maturation, we evaluated their surface 
expression of CD80, CD86, CD40, CD83, HLA-DR molecules. As shown in Figure 2B, 
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CD91bright moDCs expressed significantly higher levels of all the activation and maturation 
markers compared to CD91dim moDCs: CD80 (MFI, mean ± SE, 905 ± 116 vs. 647 ± 95, 
P<0.05), CD86 (MFI, 4864 ± 861 vs. 3093 ± 473, P=0.05), CD40 (MFI, 1287 ± 157 vs. 813 ± 
125, P<0.01), CD83 (MFI, 1235 ± 99 vs. 865 ± 120, P<0.01) and HLA-DR (MFI, 32273 ± 
6815 vs. 20578 ± 6862, P<0.05). As shown in the same Figure, CD91bright moDCs expressed 
significantly higher levels of CCR7 than CD91dim moDCs (MFI, 3814 ± 649 vs. 1520 ± 185, 
P=0.01) 
 
rHNP-1 and rHBD-1 increase the proportion of the CD91bright moDC subset 
Based on our previous findings indicating that moDC treatment with human defensins up-
regulates the surface expression of CD91, we next evaluated whether in vitro stimulation 
with rHNP-1 and rHBD-1 may indeed positively affect the frequency of CD91bright moDCs. 
Interestingly, we observed that the proportion of CD91bright moDCs increased after rHNP-1 
stimulation by 45.4 ± 15.4 % (mean ± SE, P<0.01) and after rHBD-1 stimulation by 47.0 ± 
17.4% (P<0.05). On the contrary, the proportion of CD91bright moDCs decreased after 
treatment with the CD91 ligand HSP90 by -32.7 ± 6.2 % (P<0.05) and after LPS stimulation 
by -34.0 ± 8.9% (P<0.05) (Figures 3A and 3B).  
 
rHNP-1 and rHBD-1 increase the activation of CD91bright moDC subset 
Next, we performed experiments to test the ability of CD91bright moDCs to respond to 
defensins. First, we confirmed previously published data that both defensins promoted the 
activation and maturation of total moDCs: rHNP-1 vs. unstimulated CD80 (MFI, mean ± SE, 
739 ± 37 vs. 611 ± 39, P<0.05), CD86 (3482 ± 1162 vs. 2984 ± 557, P=ns), CD40 (1432 ± 
101 vs. 1018.16 ± 174, P<0.05), CD83 (1288 ± 252 vs. 738 ± 165, P<0.05) and HLA-DR 
(24026 ± 3209 vs. 14490 ± 3905, P<0.05); rHBD-1 vs. unstimulated CD80 (830 ± 64 vs. 611 
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± 39, P<0.05), CD86 (5327 ± 1589 vs. 2984 ± 557, P=ns), CD40 (1549 ± 145 vs. 1018.16 ± 
174, P<0.05), CD83 (1229 ± 253 vs. 738 ± 165, P=ns) and HLA-DR (26580 ± 4690 vs. 
14490 ± 3905, P<0.05) (Figure 4). We further analysed the in vitro effects of rHNP-1, rHBD-
1 and LPS stimulation on CD91bright compared with CD91dim moDCs. As shown in the same 
Figure, rHNP-1 induced significantly higher levels of all the activation markers on CD91bright 
moDCs compared to CD91dim moDCs (MFI on CD91bright vs. CD91dim cells, CD80: 864 ± 51 
vs. 721 ± 45, P<0.05; CD86: 4373 ± 1260 vs. 3463 ± 1154, P<0.05; CD40: 2164 ± 289 vs. 
1367 ± 132, P<0.05; HLA-DR: 40483 ± 5467 vs. 23769 ± 7002, P<0.05). Similar results were 
observed when moDCs were stimulated with rHBD-1 (CD80: 1216 ± 264 vs. 1012 ± 190, 
P<0.05; CD40: 1956 ± 138 vs. 1323 ± 196, P<0.05; CD83: 1775 ± 279 vs. 1224 ± 253, 
P<0.05; HLA-DR: 41818 ± 5536 vs. 26457 ± 3637, P<0.05). Conversely, when moDCs were 
stimulated with LPS, no significant differences in the expression of any activation marker 
was observed between CD91bright and CD91dim cells. Overall, these results indicate that 
CD91bright moDCs undergone stimulation with rHNP-1 and rHBD-1 maintained their higher 
state of activation/maturation compared to CD91dim moDCs while this property was lost upon 
LPS stimulation. 
 
Discussion 
DCs are potent antigen presenting cells that sense environmental stimuli through a wide 
repertoire of receptors expressed on their surface.18 We and others previously described that 
moDCs express CD91, a polyfunctional receptor that binds several molecules including 
defensins.4,9,15-17 In this study we confirmed our previous observations and, by using 
multiparametric flow cytometry analysis, we showed for the first time to our knowledge the 
presence of two distinct subsets of moDCs based on their CD91 expression: CD91bright and 
CD91dim moDCs. These subsets were characterized by a different phenotype. In fact, 
although CD91bright cells represented a small proportion of moDCs, this subset showed a 
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higher expression of activation/maturation markers compared to CD91dim moDCs, 
suggesting that these two subsets could have different roles in the immune response. This 
hypothesis may be further supported by a previous study that correlated the full maturation 
status of pDCs with a greater increase of CD91 expression and increased CD91 ligand 
binding capacity.19 Interestingly, in our study in vitro stimulation with defensins increased the 
proportion of CD91bright moDCs and preserved their higher activation/maturation status 
compared to CD91dim moDCs, suggesting that CD91bright moDCs may be more sensitive to 
CD91 stimulation. Notably, defensins appeared unique in their ability to up-regulate their 
own receptor, as CD91 up-regulation was not shared by HSP90, another CD91 ligand highly 
expressed in eukariotic cells. Indeed, in accordance to one of two previous studies 
addressing the effects of HSPs on the expression of CD91 on different antigen presenting 
cells,19,20 we observed that HSP90 decreased the frequency of CD91bright moDCs. Not even 
the ability of defensins to up-regulate CD91 was shared by LPS, a common pro-
inflammatory molecule that signals through toll-like receptor 4. Indeed, also LPS decreased 
the frequency of CD91bright moDCs. This finding is in accordance with our previous study,15  
reporting LPS-induced down-regulation of CD91 expression on moDCs, possibly supported 
by shedding of CD91 from cell surface.21  
 
Although there are evidences that CD91-mediated immune activation can represent a 
powerful mechanism of immune regulation, the pathway/s regulating expression of CD91 
have not been fully defined so far. CD91 is up-regulated on monocytes of HIV+ long term 
nonprogressor subjects, it may enhance cross-presentation of HIV antigens and may in turn 
enhance the stimulation of activated anti-HIV CTLs.22 Moreover, the pivotal role of CD91 
regulation on DCs has been demonstrated in the context of primary effusion lymphoma: DC 
activation was completely inhibited when these cells were pre-treated with a neutralizing 
antibody directed against CD91,11 thus suggesting that the up-regulation of CD91 in cancer 
patients may represent an additional strategy to improve DC activation and subsequent 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
stimulation of a specific CD8+ T cell response. Notably, we observed that CD91bright cells 
expressed significantly higher levels of CCR7 than CD91dim cells, suggesting that CD91bright 
moDC subset might preferentially migrate to secondary lymphoid nodes, where they may 
elicit adaptive immune responses. 
 
Our results are intriguing because of the plasticity of dendritic cells in the setting of different 
immune responses. Thus, we could hypothesize a differential role of CD91bright and CD91dim 
moDC subsets in activating the immune response, possibly involving a differential production 
of pro-inflammatory and regulatory cytokines. These two cell subsets may also differentially 
privilege MHC-I rather than MHC-II presentation. Due to the low frequency of CD91bright 
moDCs in our cultures, we could not separate these populations in order to compare their 
antigen presenting abilty. Experiments of cell depletion where not undertaken, as they may 
provide only approximate and indirect functional data. Additional studies will be required in 
the future to further characterize the role of CD91bright and CD91dim DCs in the immune 
response. 
 
Taken together, our results suggest that moDCs preferentially respond to defensins by 
increasing the frequency of CD91bright moDCs and promoting a higher state of 
activation/maturation of these cells compared to CD91dim moDCs. The identification of a 
subset of moDCs expressing high levels of CD91 and molecules involved in DC-T cell 
interaction suggests that these CD91bright cells may be particularly devoted to the activation 
of adaptive immune responses against antigens that may be delivered to DCs through CD91 
ligands, in particular defensins. These results may provide new insights into the immune 
potentiating effects of defensins that are currently under intense investigation as possible 
new therapeutic agents aimed to potentiate antimicrobial and antitumor immunity. 
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Figure legends 
Figure 1. The expression of CD91 is partially down-regulated during differentiation of 
monocytes into moDCs. Monocytes obtained by plastic adhesion from freshly isolated 
PBMCs were stained for surface expression of CD14, CD1a and CD91 before and after their 
differentiation into moDCs obtained by 5 day-culture with rhGM-CSF and rhIL-4. (A) Dot 
plots showing the gating strategy and the expression of CD14 and CD1a on monocytes 
(upper row) and moDCs (lower row). (B) Histogram showing the mean fluorescence intensity 
(MFI) of CD91 expression on monocytes (gray line), moDCs (black line), and FMO negative 
control (dotted line). One representative experiment is shown. 
 
Figure 2. Different levels of CD91 identify two moDC subpopulations. Immature moDCs 
were stained for surface expression of CD91 and activation/maturation markers. (A) 
Representative flow cytometric analysis showing the gating strategy used to define CD91dim 
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and CD91bright moDCs. (B) Graphs show the mean fluorescence intensity (MFI) of CD80, 
CD86, CD40, CD83, CCR7 and HLA-DR molecules in CD91dim (white bars) and CD91bright 
(black bars) moDCs from 11 independent experiments. Data shown as mean ± SE. * p<0.05, 
** p<0.01.  
 
Figure 3. rHNP-1 and rHBD-1 increase the proportion of CD91bright moDC subset. 
Immature moDCs were incubated with 100 ng/ml rHNP-1, 500 ng/ml rHBD-1, 20 μg/ml 
HSP90 or 100 ng/ml LPS. After 18 hr, the cells were analyzed by flow cytometry to measure 
cell-surface CD91 expression. (A) Representative flow cytometric analysis showing the 
increased proportion of CD91bright moDC subset after rHNP-1 and rHBD-1 stimulation 
compared to the decreased proportion after HSP90 and LPS challenge. (B) Change of 
CD91bright moDCs frequency after rHNP-1, rHBD-1, HSP90 and LPS compared to 
unstimulated conditions. Data shown as mean ± SE from 6 independent experiments.        * 
p<0.05, ** p<0.01. 
 
Figure 4. HNP-1 and HBD-1 increase the activation of CD91bright moDC subset.  
Immature moDCs were stimulated with 100 ng/ml rHNP-1, 500 ng/ml rHBD-1, or 100 ng/ml 
LPS. After 18 h, the cells were analyzed by flow cytometry to measure cell-surface activation 
and maturation markers expression on total moDCs (white bars), CD91dim moDCs (black 
bars) and CD91bright moDCs (shaded bars). Graphs show the mean fluorescence intensity 
(MFI) of CD80, CD86, CD40, CD83 and HLA-DR molecules. Data shown as mean ± SE 
from 6 independent experiments and analyzed by the paired t-test). #: p<0.05 stimulated 
total moDCs compared to unstimulated (NS) cells; * p<0.05: CD91dim moDCs compared with 
CD91bright moDCs. 
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